What is it about?
A widely covered study reported that cancer patients getting an mRNA COVID vaccine near the start of immunotherapy lived much longer, and suggested mRNA vaccines uniquely wake up the immune system to help the treatment work. Using nationwide Medicare data on over 120,000 cancer patients, we compared mRNA, non-mRNA COVID, and flu vaccines. All three showed a similar extra survival benefit for immunotherapy patients, so we found no evidence the effect is specific to mRNA vaccines.
Featured Image
Photo by Diana Polekhina on Unsplash
Why is it important?
Rather than just comparing groups, we ran a formal statistical test for whether the effect is mRNA-specific. A platform-specific effect would have major implications for cancer care, so it's important to know the evidence doesn't support an mRNA specific effect.
Perspectives
This project started because a striking claim in a widely covered paper caught my interest. Looking closer, some methodological doubts crept in, and we wanted to actually test them rather than simply take the claim at face value. It turned out our data showed a similar survival benefit, but one that wasn't specific to mRNA vaccines, which is hard to reconcile with the original paper's claim. Importantly, we formally tested the very thing the original paper asserted but never actually tested, and once we did, I didn't see evidence to support the mRNA-specific explanation that had first caught my attention.
René Karadakic
Eidgenössische Technische Hochschule Zürich
Read the Original
This page is a summary of: Interpreting vaccine-associated survival differences in immune checkpoint inhibitor therapy, Proceedings of the National Academy of Sciences, August 2026, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2621501123.
You can read the full text:
Contributors
The following have contributed to this page
